Physician profile
Daniel Sims
NPI 1669836532
$1,676.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.95 · 2021: $352 · 2022: $694 · 2023: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.60 |
| Education | $127.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $280.23 | 2021-2022 | |
| Seagen INC. | $251.93 | 2020-2023 | |
| Daiichi Sankyo INC. | $183.90 | 2022-2023 | Enhertu, Injectafer |
| Astellas Pharma US INC | $175.78 | 2022-2023 | |
| Lilly USA, LLC | $138.61 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $128.50 | 2022-2023 | Iclusig |
| Novartis Pharmaceuticals Corporation | $127.38 | 2022-2023 | |
| Janssen Biotech, INC. | $123.34 | 2022-2023 | Erleada |
| Astrazeneca Pharmaceuticals Lp | $116.87 | 2023 | Imfinzi, Tagrisso |
| Genentech USA, INC. | $40.73 | 2022-2023 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $27.61 | 2023 | Libtayo |
| Merck Sharp & Dohme LLC | $24.41 | 2023 | Keytruda |
| Amgen INC. | $21.26 | 2023 | Kyprolis, Blincyto |
| Pharmacosmos Therapeutics INC. | $20.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.